Vir Biotechnology

General Information
Business:

We are a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Infectious diseases are one of the leading causes of death worldwide and cause hundreds of billions of dollars of economic burden each year. We believe that now is the time to apply the recent and remarkable advances in immunology to combat infectious diseases. Our approach begins with identifying the limitations of the immune system in combating a particular pathogen, the vulnerabilities of that pathogen and the reasons why previous approaches have failed. We then bring to bear powerful technologies that we believe, individually or in combination, will lead to effective therapies.

Industry: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)
Employees: 206
Founded: 2016
Contact Information
Address 499 Illinois Street, Suite 500, San Francisco, CA 94158, US
Phone Number (415) 906-4324
Web Address http://www.vir.bio
View Prospectus: Vir Biotechnology
Financial Information
Market Cap $2187.9mil
Revenues $11.7 mil (last 12 months)
Net Income $-122.4 mil (last 12 months)
IPO Profile
Symbol VIR
Exchange NASDAQ
Shares (millions): 7.1
Price range $20.00 - $20.00
Est. $ Volume $142.9 mil
Manager / Joint Managers Goldman Sachs/ J.P. Morgan/ Cowen/ Barclays
CO-Managers -
Expected To Trade: 10/11/2019
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change